199 related articles for article (PubMed ID: 12161478)
1. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
Passos VQ; Souza JJ; Musolino NR; Bronstein MD
J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
[TBL] [Abstract][Full Text] [Related]
2. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
4. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
5. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
7. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
8. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
10. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
[TBL] [Abstract][Full Text] [Related]
11. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
12. Rapid re-enlargement of a macroprolactinoma after initial shrinkage in a young woman treated with bromocriptine.
Adler I; Barsi P; Czirják S; Varga I; Gergics P; Jakab C; Rácz K
Gynecol Endocrinol; 2005 Jun; 20(6):317-21. PubMed ID: 16019380
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bromocriptine in the treatment of macroprolactinomas.
Essaïs O; Bouguerra R; Hamzaoui J; Marrakchi Z; Hadjri S; Chamakhi S; Zidi B; Ben Slama C
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):524-31. PubMed ID: 12527854
[TBL] [Abstract][Full Text] [Related]
15. Gender-related differences in prolactin secretion in pituitary prolactinomas.
Nishioka H; Haraoka J; Akada K; Azuma S
Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
[TBL] [Abstract][Full Text] [Related]
16. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
17. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
[TBL] [Abstract][Full Text] [Related]
19. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
20. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
